TCT-89 Percutaneous Leaflet Therapy of Severe Primary Mitral Regurgitation: Totality of Evidence From the EVEREST II Randomized, Continued Access, and High Risk Clinical Programs

Abstract

a degenerative MR patient after 3.2 years. There were no strokes with an average follow-up of 2.4 1.8 years. There were sustained improvements in New York Heart Association class (from 2.8 0.6 to 1.6 0.5, p <0.001) and MR grade (from 3.5 0.9 to 0.4 0.5, p <0.001) at follow-up. Conclusions: In this large single center experience, no patient required urgent cardiac surgery for failed MitraClip procedure. Mitral valve repair rate in patients with degenerative MR was high, and surgical options were preserved in the remaining patients. Overall, cardiac surgical outcomes were excellent.